NEW
Dupixent

Dupixent

dupilumab

Manufacturer:

sanofi-aventis

Distributor:

DKSH
Concise Prescribing Info
Contents
Dupilumab
Indications/Uses
Moderate to severe atopic dermatitis in patients ≥12 yr inadequately controlled w/ topical prescription therapies or when those therapies are not advisable, can be used w/ or w/o topical corticosteroids.
Dosage/Direction for Use
SC Adult & adolescent 12-17 yr, ≥60 kg Initially 600 mg, followed by 300 mg every other wk. Adolescent 12-17 yr, <60 kg Initially 400 mg, followed by 200 mg every other wk.
Contraindications
Special Precautions
Discontinue use if hypersensitivity reaction occurs. Not to be inj into tender, damage, bruised or scarred skin. Conjunctivitis, keratitis; comorbid asthma; parasitic helminth infections. Immunogenicity. Avoid abrupt discontinuation of systemic or local corticosteroids. Pregnancy & lactation. Ped patients <12 yr.
Adverse Reactions
Inj site reactions, conjunctivitis, blepharitis, oral herpes, keratitis, eye pruritus, other herpes simplex virus infection, dry eye.
Drug Interactions
Avoid use w/ live & non-live vaccines.
ATC Classification
D11AH05 - dupilumab ; Belongs to the class of agents for atopic dermatitis, excluding corticosteroids. Used in the treatment of atopic dermatitis.
Presentation/Packing
Form
Dupixent soln for inj 200 mg/1.14 mL
Packing/Price
2 × 1's
Form
Dupixent soln for inj 300 mg/2 mL
Packing/Price
2 × 1's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in